» Articles » PMID: 36009440

PD-L1/pS6 in Circulating Tumor Cells (CTCs) During Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)

Overview
Journal Biomedicines
Date 2022 Aug 26
PMID 36009440
Authors
Affiliations
Soon will be listed here.
Abstract

The PD-1/PD-L1 axis provides CTCs an escape route from the immune system. Phosphorylation of the ribosomal protein S6 is implicated in the same pathway, following mTOR activation. The aim of the study was to investigate the expression of PD-L1 and pS6 in CTCs from NSCLC patients under Osimertinib treatment at a single cell level. CTCs were isolated using ISET from NSCLC patients’ blood [37 at baseline, 25 after the 1st cycle, and 23 at the end of treatment (EOT)]. Staining was performed using immunofluorescence. Cytokeratin-positive (CK+) CTCs were detected in 62% of patients. CK+PD-L1+CD45− and CK+pS6+ phenotypes were detected in 38% and 41% of the patients at baseline, in 28% and 32% after 1st cycle, and in 30% and 35% at EOT, respectively. Spearman’s analysis revealed statistically significant correlations between PD-L1 and pS6 phenotypes at all time points. Survival analysis revealed that CK+pS6+ (p = 0.003) and CKlowpS6+ (p = 0.021) phenotypes after 1st cycle were related to significantly decreased one-year progression-free survival (PFS12m) and PFS, respectively. CK+PD-L1+CD45−phenotype at baseline and after 1st cycle showed a trend for decreased PFS12m. Increased expression of PD-L1/pS6 in CTCs of Osimertinib-treated NSCLC patients implies the activation of the corresponding pathway, which is potentially associated with poor clinical outcomes.

Citing Articles

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.

Ntzifa A, Marras T, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E Front Oncol. 2024; 14:1435537.

PMID: 39497713 PMC: 11532185. DOI: 10.3389/fonc.2024.1435537.


Liquid biopsy for human cancer: cancer screening, monitoring, and treatment.

Wang H, Zhang Y, Zhang H, Cao H, Mao J, Chen X MedComm (2020). 2024; 5(6):e564.

PMID: 38807975 PMC: 11130638. DOI: 10.1002/mco2.564.


Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.

Andrikou K, Rossi T, Verlicchi A, Priano I, Cravero P, Burgio M Int J Mol Sci. 2023; 24(22).

PMID: 38003273 PMC: 10671094. DOI: 10.3390/ijms242216085.


Effectiveness comparison of third-generation EGFR-TKI as initial and sequential therapy in adjuvant treatment for EGFR mutation-sensitive stage IIIA non-small cell lung cancer after surgery.

Ma W, Sheng Z, Niu Y, Yan B, Chen Y, Yang H Heliyon. 2023; 9(11):e20955.

PMID: 37920491 PMC: 10618502. DOI: 10.1016/j.heliyon.2023.e20955.

References
1.
Sun S . Searching for the real function of mTOR signaling in the regulation of PD-L1 expression. Transl Oncol. 2020; 13(12):100847. PMC: 7451686. DOI: 10.1016/j.tranon.2020.100847. View

2.
Manjunath Y, Upparahalli S, Avella D, Deroche C, Kimchi E, Staveley-OCarroll K . PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. Cancers (Basel). 2019; 11(6). PMC: 6628040. DOI: 10.3390/cancers11060806. View

3.
Mondelo-Macia P, Garcia-Gonzalez J, Leon-Mateos L, Anido U, Aguin S, Abdulkader I . Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab. Mol Oncol. 2021; 15(11):2923-2940. PMC: 8564635. DOI: 10.1002/1878-0261.13094. View

4.
Ntzifa A, Strati A, Kallergi G, Kotsakis A, Georgoulias V, Lianidou E . Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. Sci Rep. 2021; 11(1):2313. PMC: 7840727. DOI: 10.1038/s41598-021-82068-9. View

5.
Ramalingam S, Vansteenkiste J, Planchard D, Cho B, Gray J, Ohe Y . Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. N Engl J Med. 2019; 382(1):41-50. DOI: 10.1056/NEJMoa1913662. View